Aeterna Zentaris (NASDAQ:AEZS) continues to spike

Aeterna Zentaris Enterprise Value over EBIT is relatively stable at the moment as compared to the past year. Aeterna Zentaris reported last year Enterprise Value over EBIT of 4.60. As of 12/28/2020, Gross Margin is likely to grow to 0.24, while Earnings before Tax are likely to drop (6.7 M). While some baby boomers are getting worried about healthcare space, it is reasonable to sum up Aeterna Zentaris. I will take a closer look at this stock and the latest sentiment generated by retail investors. This post is to show some fundamental factors affecting Aeterna Zentaris' products and services. I will also report how it may impact the investing outlook for the company in January.
Published over a year ago
View all stories for Aeterna Zentaris | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

About 4.0% of Aeterna Zentaris shares are held by institutions such as insurance companies. Insiders ownership of Aeterna Zentaris refers to the amount of Aeterna Zentaris equity owned by Aeterna officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Aeterna, including its current ownership diagnostics.
The performance of Aeterna Zentaris in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Aeterna Zentaris' stock prices. When investing in Aeterna Zentaris, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Aeterna Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Aeterna Zentaris carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.

How important is Aeterna Zentaris's Liquidity

Aeterna Zentaris financial leverage refers to using borrowed capital as a funding source to finance Aeterna Zentaris ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aeterna Zentaris financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Aeterna Zentaris' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Aeterna Zentaris' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Aeterna Zentaris's total debt and its cash.

Breaking down Aeterna Zentaris Indicators

Aeterna Zentaris holds a total of sixty-two million six hundred eighty thousand outstanding shares. Aeterna Zentaris shows 6.29 percent if its outstanding shares held by insiders and 6.29 percent owned by other corporate entities . Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 2019 2020 (projected)
Interest Expense1.36 M1.33 M
Gross Profit122 K125.21 K

Ownership Breakdown

Retail Investors
89.27%
Insiders
6.29%
Retail Investors89.27
Insiders6.29
Institutions4.44

Our perspective of the latest Aeterna Zentaris spike

Aeterna Zentaris latest skewness advances over 1.81. As of the 28th of December, Aeterna Zentaris shows the Mean Deviation of 3.45, downside deviation of 4.2, and Risk Adjusted Performance of 0.0838. Aeterna Zentaris technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Aeterna Zentaris, which can be compared to its rivals. Please confirm Aeterna Zentaris variance and potential upside to decide if Aeterna Zentaris is priced correctly, providing market reflects its regular price of 0.43 per share. As Aeterna Zentaris is a penny stock we also strongly suggest to validate its total risk alpha numbers.

While some other entities under the biotechnology industry are still a bit expensive, Aeterna Zentaris may offer a potential longer-term growth to retail investors. The inconsistency in the assessment between current Aeterna valuation and our trade advice on Aeterna Zentaris is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aeterna Zentaris.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Aeterna Zentaris. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com